Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Sionna Therapeutics, Inc. (SION)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.73+2.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SION yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash runway to fund operations into 2028 | Sionna aims to fund operations into 2028 with its current cash. | Intact | cash runway falls short of funding operations into 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is on watch: clinical programs are progressing, while recent financial performance is weak and the evidence snapshot has low overall confidence.
The snapshot gives no valuation multiple or clear evidence about what investors already expect, so valuation and the expectations gap are difficult to assess. No fragility gates fired, but that does not establish that the business is inexpensive or that expectations are low.
Near term, a next-quarter earnings miss is an elevated risk, and further cash declines or rising losses could keep pressure on the operating picture. Over the multi-year view, management has completed Phase 2a enrollment and says cash can fund operations into 2028, but the cash balance has declined and the workforce reduction signals active cost control amid growing losses.
The thesis depends on delivering the planned clinical milestones and maintaining enough cash runway while controlling operating losses. Near term, guidance cuts or weaker jobs data could add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.
Over one to three years, SION's thesis remains dependent on clinical execution and cash discipline, with weak recent results and high risk offset by programs described as on track. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating losses are managed around -$29.6M in Q1 2026. |
| Under Pressure |
| operating losses increase significantly beyond -$30M per quarter |
Operating income: $-32.47M FY2026-Q2; GAAP. Published target: Operating losses remain near or below -$30M per quarter. Target period is not explicitly aligned with this observation. Aug 6, 2026-32,470,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance pipeline toward revenue generation | A supporting condition in Sionna Therapeutics, Inc.'s published investment case. The stated target is Achieve at least $3M revenue in FY27. | Intact | revenue fails to reach $3M in FY27 | Revenue: $0 FY2026-Q2; GAAP. Published target: Achieve at least $3M revenue in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.79 → $-2.29 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.79 | $3,333,333 | 7 / 10 |
| 2026-07-25 | $-2.79 | $3,333,333 | 7 / 10 |
| 2026-07-26 | $-2.83 | $3,000,000 | 7 / 10 |
| 2026-07-27 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-07-28 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-07-29 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-07-30 | $-2.83 | $3,000,000 | 7 / 10 |
| 2026-07-31 | $-2.83 | $3,000,000 | 7 / 10 |
| 2026-08-01 | $-2.83 | $3,000,000 | 7 / 10 |
| 2026-08-02 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-08-03 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-08-04 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-08-05 | $-2.83 | $3,000,000 | 7 / 10 |
| 2026-08-06 | $-2.80 | $3,000,000 | 9 / 10 |
| 2026-08-08 | $-2.83 | $3,333,330 | 9 / 9 |
| 2026-08-09 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-10 | $-2.83 | $3,333,330 | 9 / 9 |
| 2026-08-12 | $-2.53 | $0 | 9 / 10 |
| 2026-08-13 | $-2.53 | $0 | 9 / 10 |
| 2026-08-14 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-15 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-16 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-17 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-18 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-19 | $-2.83 | $2,727,273 | 7 / 10 |
| 2026-08-20 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-21 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-22 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-23 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-24 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-25 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-26 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-27 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-28 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-29 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-30 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-08-31 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-01 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-02 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-03 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-04 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-05 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-06 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-07 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-08 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-09 | $-2.55 | $2,727,273 | 7 / 10 |
| 2026-09-10 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-11 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-12 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-13 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-14 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-15 | $-2.55 | $2,727,273 | 8 / 10 |
| 2026-09-16 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-17 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-18 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-19 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-20 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-21 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-22 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-23 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-24 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-25 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-26 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-27 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-28 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-29 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-09-30 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-01 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-02 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-03 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-04 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-05 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-06 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-07 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-08 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-09 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-10 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-11 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-12 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-13 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-14 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-15 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-16 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-17 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-18 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-19 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-20 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-21 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-22 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-23 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-24 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-25 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-26 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-27 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-28 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-29 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-30 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-10-31 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-11-01 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-11-02 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-11-03 | $-2.29 | $2,727,273 | 8 / 10 |
| 2026-11-04 | $-2.29 | $2,727,273 | 8 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 10 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.